Harbor Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Harbor Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.42M	Sell	72,316 -10,880	-13%	-$270K	0.16%	173
2026 Q1	$1.74M	Buy	+83,196	New	+$1.87M	0.14%	220
2024 Q1	–	Sell	-34,930	Closed	-$1.67M	–	837
2023 Q4	$1.67M	Buy	34,930 +3,048	+10%	+$118K	0.32%	81
2023 Q3	$1.14M	Buy	31,882 +5,910	+23%	+$234K	0.24%	103
2023 Q2	$1.2M	Buy	+25,972	New	+$1.2M	0.24%	105
2023 Q1	–	Sell	-2,264	Closed	-$105K	–	269
2022 Q4	$105K	Buy	2,264 +469	+26%	+$18.4K	0.1%	85
2022 Q3	$74K	Sell	1,795 -1,123	-38%	-$57.7K	0.07%	134
2022 Q2	$174K	Buy	2,918 +592	+25%	+$36.4K	0.13%	87
2022 Q1	$169K	Buy	+2,326	New	+$162K	0.08%	113

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Harbor Capital Advisors's RARE Position: Q2 2026 in Review

Harbor Capital Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 13% in Q2 2026, selling an estimated $270K and leaving 72,316 shares worth $2.42M. The position accounts for 0.16% of the portfolio, ranked #173.

Harbor Capital Advisors first reported a position in RARE in Q1 2022 and has held it in 9 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Harbor Capital Advisors held 72,316 shares of Ultragenyx Pharmaceutical worth $2.42M as of Q2 2026.
Harbor Capital Advisors sold 10,880 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $270K.
Ultragenyx Pharmaceutical made up 0.16% of Harbor Capital Advisors's portfolio in Q2 2026, its #173 holding.
Harbor Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and has held it in 9 quarters since.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.